mRNA-4157 is a personalised vaccine targeting 34 cancer neoantigens, derived from a biopsy of a patient's tumour. In June, Moderna and MSD said they may be able to move ahead with regulatory ...
Moderna reports larger-than-expected quarterly loss Revenue falls 66% but beats expectations FDA pauses norovirus vaccine trial after adverse event report Feb 14 (Reuters) - Moderna (MRNA.O ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback